[
  {
    "ts": null,
    "headline": "“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom",
    "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare product",
    "url": "https://finnhub.io/api/news?id=f498b6e28c5d1e477ab1e64d6e2cd9b5ede13dcfe58acbc3da28342671922722",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763076600,
      "headline": "“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom",
      "id": 137477135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare product",
      "url": "https://finnhub.io/api/news?id=f498b6e28c5d1e477ab1e64d6e2cd9b5ede13dcfe58acbc3da28342671922722"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript",
    "summary": "Biogen Inc. (BIIB) TD Cowen Immunology and Inflammation Summit November 13, 2025 4:30 PM ESTCompany ParticipantsDiana GallagherConference Call...",
    "url": "https://finnhub.io/api/news?id=f9715545ad8e931715a7e642795a6420f9435372ca0d3c85ac67f0fdfa89dbc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763059300,
      "headline": "Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript",
      "id": 137474105,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (BIIB) TD Cowen Immunology and Inflammation Summit November 13, 2025 4:30 PM ESTCompany ParticipantsDiana GallagherConference Call...",
      "url": "https://finnhub.io/api/news?id=f9715545ad8e931715a7e642795a6420f9435372ca0d3c85ac67f0fdfa89dbc9"
    }
  },
  {
    "ts": null,
    "headline": "Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal",
    "summary": "AFPs promise to connect patients with more-affordable options for accessing specialty medications that often come at very high costs. There's a major catch.",
    "url": "https://finnhub.io/api/news?id=4fc23f7aefeb8a8f1eea326dc78ce4d5a2651fad01eb4158ba145cdeb0eea55c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763020801,
      "headline": "Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal",
      "id": 137469809,
      "image": "https://image.cnbcfm.com/api/v1/image/108223038-1762527694430-gettyimages-1331673370-img_6509copy.jpeg?v=1762527708&w=1920&h=1080",
      "related": "BIIB",
      "source": "CNBC",
      "summary": "AFPs promise to connect patients with more-affordable options for accessing specialty medications that often come at very high costs. There's a major catch.",
      "url": "https://finnhub.io/api/news?id=4fc23f7aefeb8a8f1eea326dc78ce4d5a2651fad01eb4158ba145cdeb0eea55c"
    }
  }
]